Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of PG4 multivalent pneumococcal conjugate vaccine in healthy toddlers
2025-000101-16Phase 2
- Sponsor
- Pfizer
- Start
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pneumococcal disease comparing PG4 vaccine arm with 20vPnC control arm (2 arms). Primary endpoint: Percentage of participants reporting prespecified local reactions within 7 days after each dose.
02
Drugs
PG4 multivalent pneumococcal conjugate vaccinePrevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2025-000101-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000101-16.